- Home
- SLVM vs DNLI Comparison
SLVM vs DNLI Comparison
Compare SLVM & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLVM
- DNLI
- Stock Information
- Founded
- SLVM 1898
- DNLI 2013
- Country
- SLVM United States
- DNLI United States
- Employees
- SLVM N/A
- DNLI N/A
- Industry
- SLVM Paper
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLVM Basic Materials
- DNLI Health Care
- Exchange
- SLVM Nasdaq
- DNLI Nasdaq
- Market Cap
- SLVM 2.4B
- DNLI 2.1B
- IPO Year
- SLVM N/A
- DNLI 2017
- Fundamental
- Price
- SLVM $45.43
- DNLI $15.43
- Analyst Decision
- SLVM Hold
- DNLI Strong Buy
- Analyst Count
- SLVM 3
- DNLI 15
- Target Price
- SLVM $75.00
- DNLI $33.62
- AVG Volume (30 Days)
- SLVM 519.9K
- DNLI 2.0M
- Earning Date
- SLVM 08-08-2025
- DNLI 11-05-2025
- Dividend Yield
- SLVM 3.97%
- DNLI N/A
- EPS Growth
- SLVM N/A
- DNLI N/A
- EPS
- SLVM 5.23
- DNLI N/A
- Revenue
- SLVM $3,550,000,000.00
- DNLI N/A
- Revenue This Year
- SLVM N/A
- DNLI N/A
- Revenue Next Year
- SLVM $1.88
- DNLI $802.87
- P/E Ratio
- SLVM $8.68
- DNLI N/A
- Revenue Growth
- SLVM N/A
- DNLI N/A
- 52 Week Low
- SLVM $37.52
- DNLI $10.57
- 52 Week High
- SLVM $98.02
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- SLVM 49.65
- DNLI 56.61
- Support Level
- SLVM $43.34
- DNLI $14.52
- Resistance Level
- SLVM $46.45
- DNLI $16.20
- Average True Range (ATR)
- SLVM 1.37
- DNLI 0.70
- MACD
- SLVM 0.34
- DNLI -0.01
- Stochastic Oscillator
- SLVM 83.60
- DNLI 62.44
About SLVM Sylvamo Corporation
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.